

BridgeBio ATTR-CM Fellowship Grant RFP

Overview: To support a one-year (52 week) fellowship for purposes of clinical training of physicians and/or advanced practice practitioners (Nurse Practitioners and Physician Assistants) in ATTR cardiac amyloidosis (ATTR-CM), and support research in ATTR-CM.

Geographic Scope: United States

Candidates: Cardiologists, Cardiology Fellows, Nurse Practitioners and Physician Assistants

Eligible Program Types:

- Emerging new programs in ATTR-CM to train candidates clinically and facilitate research.
- Established ATTR-CM programs with structured training and research; preferred institutions have a strong focus on clinical training, research and education to further the understanding of transthyretin cardiac amyloidosis.

Areas of Interest: Education and Research in the evolving landscape of ATTR-CM.

Key Milestones:

- Application submission deadline: June 1, 2025
- Anticipated Notification Date: Rolling based on submission
- Anticipated Project Start Date: July 2025
- Funding: \$90,000 to support a one-year fellowship. Fellowships are awarded to directly support salaries and limited fringe benefits of fellows.

Eligibility

- Applicant Eligibility Criteria
 - I. The fellowship grant will be requested by and awarded to an accredited, US based institution, not an individual.
 - II. Fellowship request must be for a future program and a fellowship grant may not be renewed for a fellow previously selected by the organization using BridgeBio funds.
 - III. No aspect of the program can provide tangible benefit BridgeBio.
 - IV. Fellow time spent in the clinical setting that is supported through grant funds cannot be billed as patient care.
 - V. Funds are not tied in any way to past, present, or future purchasing, prescribing, or recommending BridgeBio products or services.
 - VI. Funding is awarded to qualified U.S. based academic or accredited medical institutions only; fellowship funding from BridgeBio will not be given directly to individual fellows.
 - VII. BridgeBio must not be the single source of funds for the fellowship; encourages support from other pharmaceutical/biotechnology companies, in addition to BridgeBio, and the institution itself, to support the program.

- VIII. Fellowship requests should not disclose the name of the fellow in the application.
- IX. The requesting organization must confirm receipt of payment and verify how funds were used for all previous BridgeBio supported activities, in accordance with the Sunshine Act reporting parameters.
- X. Requesting organization and fellowship request must be in full compliance with all regional and local codes, laws and industry regulations, including, but not limited to anti-corruption, transparency and privacy laws and regulations.
- XI. Organizations may not use awarded funds to defray operating expenses or overhead costs.
- XII. Must utilize Faculty who devote sufficient time to fulfill their supervisory and teaching responsibilities.

RFP Date

• Date RFP Issued: April 11, 2025

Requirements for Prospective Fellows:

- U.S. Physician Payments Sunshine Act and other transparency law requirements must be satisfied with respect to meals, payments and other transfers of value provided by BridgeBio. As a condition of this grant, the selected fellow will be identified in transparency reporting as a recipient of grant funding.
- Be a U.S. citizen or a legal permanent resident of the United States; fellowship candidates with temporary nonimmigrant visa categories are not eligible.
- Have a sponsor who is a full-time faculty member of the requesting organization.
- Not hold a full-time, tenure-track faculty position or its equivalent during the first year of the fellowship.
- Have not previously held a fellowship funded by BridgeBio.
- Fellowship candidates must hold an active MD, DO, NP-BC or PA-C license in good standing.

<u>Budget</u>

• Grant funding is available to support one (1) fellow for up to one (1) year for \$90,000. The budget can only include salary and support for the fellow's benefits.

Submission Process

Submit to: Kristen Binaso, RPh Senior Director, Professional Society Engagements & Educational Partnerships <u>Kristen.Binaso@bridgebio.com</u>

Questions:

• If you have any questions regarding this RFP, please direct them to Kristen Binaso at Kristen.Binaso@bridgebio.com

Review and Approval Process

- Funding decisions for Fellowships are made through a formal, centralized review and decision-making process.
- Proposals will be evaluated based on a number of criteria including: Fellowship goals, medical needs and population health, patient journey, barriers to care/diagnosis, mentoring, patient care experience, utilization of technology for early/accurate diagnosis.
- BridgeBio will conduct appropriate due diligence on all requesting organizations and fellowship requests.
- BridgeBio reserves the right to deny any fellowship request that does not meet application and eligibility requirements.
- BridgeBio does not provide any substantive input or assistance to a requesting organization in drafting or submitting a grant request.
- BridgeBio must not be involved in the selection of the fellow.
- BridgeBio may modify the fellowship application and eligibility requirements at any time.

Mechanism by which Applicants will be Notified:

• All recipient organizations must abide by the terms and conditions as outlined in the Letter of Agreement (LOA)/contract. The LOA/contract is issued electronically to an authorized signatory of the organization once an application is approved. A fully executed LOA/contract is required prior to the start of the program and for payment.